The FDA has approved the first blood test for Alzheimer's disease based on a blood test – from Fujirebio – in a step forward ...

STOCKHOLM, May 15, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately SEK ...

US regulators have approved the first blood test to help diagnose Alzheimer’s disease, potentially making it easier to find ...

The FDA has approved the first blood test for diagnosing Alzheimer’s disease, which could speed the path to treatment for ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately SEK 5.1 billion) for their fiscal year (FY) 2025 ...

The U.S. Food and Drug Administration has cleared Fujirebio Diagnostics' blood test to diagnose Alzheimer's disease, the ...

U.S. regulators have approved the first blood test to help diagnose Alzheimer’s disease, potentially making it easier to find ...